Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry
Abstract Risk-reducing endocrine therapy use, though the benefit is validated, is extremely low. The FDA has approved tamoxifen and raloxifene for a 5-year Breast Cancer Risk Assessment Tool (BCRAT) risk ≥ 1.67%. We examined the threshold at which high-risk women are likely to be using endocrine ris...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/91eaf37ec54149658dd7d48f84d13d80 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|